Phaseline

Companies › Altimmune

Altimmune: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 2; Gastroenterology, Metabolic and endocrine; next expected readout Sep 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Pemvidutide
GLP-1 and glucagon receptor dual agonist
GLP1R, GCGRPhase 3Metabolic Dysfunction-Associated Steatohepatitis (MASH); Alcohol-associated Liver DiseaseSep 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07009860PemvidutidePhase 2Alcohol-associated Liver DiseaseGastroenterologySep 2027
NCT07795164PemvidutidePhase 3Metabolic Dysfunction-Associated Steatohepatitis (MASH)Metabolic and endocrineDec 2028

From the company's SEC filings

Cash and short-term investments of $326m on 2026-06-30; operating cash outflow about $92m a year; runway about 43 months at that burn, to Jan 2030; 2 of 2 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Specialist investors

Held by 10 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

GLP1R (1) GCGR (1)

Companies with the same targets

Eli Lilly Novo Nordisk Roche AstraZeneca Hanmi Pharmaceutical Company Hangzhou Sciwind Biosciences Boehringer Ingelheim Hangzhou Zhongmei Huadong Pharmaceutical Hudson Biotech Amgen

Companies built like this

VectivBio Kailera Camurus Ascendis Pharma Bone Diseases BioXTek

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.